Peer-reviewed veterinary case report
Effectiveness and side effects of PMPDAP in cats with feline
By Justa, N et al.·Published in Journal of veterinary internal medicine·2012·Clinic of Small Animal Medicine, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy and adverse effects of (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine in feline immunodeficiency virus-infected cats.
- Species:
- cat
Plain-English summary
A group of 45 cats infected with feline immunodeficiency virus (FIV) were treated with a new medication called PMPDAP to see if it could help improve their health. Unfortunately, the treatment did not show any benefits in terms of their overall health or virus levels, and it even caused some cats to develop anemia, which is a decrease in red blood cells. Because of these adverse effects and lack of improvement, PMPDAP is not recommended for treating FIV in cats.
People also search for: FIV treatment for cats · anemia in cats symptoms · feline immunodeficiency virus medication
Abstract
BACKGROUND: (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP) is active against feline immunodeficiency virus (FIV) in vitro, and is less toxic than other acyclic nucleoside phosphonates. Its efficacy in naturally infected cats has not been evaluated in large controlled studies. HYPOTHESIS/OBJECTIVES: PMPDAP is effective in naturally FIV-infected cats with minimal adverse effects. ANIMALS: Forty-five privately owned cats naturally infected with FIV. METHODS: Prospective, randomized, placebo-controlled, double-blinded clinical study. Cats were randomly assigned to be treated with PMPDAP (25 mg/kg) daily, PMPDAP 3 times a week, or placebo for a period of 6 weeks. RESULTS: Administration of PMPDAP to FIV-infected cats did not lead to detectable improvements in clinical, virological, or immunological variables. Proviral load (FIV copies/10(6) cells) did not change significantly during treatment (placebo group: from 9505 ± 10119 to 8564 ± 8615; PMPDAP 3 times a week: from 4818 ± 4426 to 5041 ± 6197; PMPDAP daily: from 3525 ± 5038 to 3167 ± 5824). There was a significant decrease of red blood cell counts (×10(12) /L) (from 8.91 ± 1.82 to 7.34 ± 1.79 in cats treated 3 times per week (P < .001), and from 8.96 ± 1.13 to 6.01 ± 1.36 in cats treated daily (P < .001)), as well as of packed cell volume, and hemoglobin in both groups receiving PMPDAP. CONCLUSIONS AND CLINICAL IMPORTANCE: Administration of PMPDAP was not associated with significant improvements in clinical, immunological, or virological parameters, but treatment was associated with adverse effects, mainly anemia. Thus, PMPDAP, as administered in this study, cannot be recommended for treatment of FIV-infected cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23039914/